This act establishes non-mandatory guidance for private employers and mandatory regulations for federal agencies regarding the acquisition, maintenance, and training for opioid overdose reversal medication in the workplace.
Bonnie Watson Coleman
Representative
NJ-12
The WORK to Save Lives Act aims to combat opioid overdoses by requiring federal agencies to stock overdose reversal medication and provide voluntary training. For private employers, the bill establishes non-mandatory guidance on acquiring medication and offering similar voluntary employee training. This legislation focuses on increasing the availability and knowledge surrounding life-saving overdose reversal tools in workplaces.
The WORK to Save Lives Act introduces a two-track strategy to combat opioid overdoses where many people spend the bulk of their day: at work. Under Section 3 of the bill, every federal agency—ranging from the Department of Agriculture to the Veterans Health Administration—will be required to acquire and maintain opioid overdose reversal medications, such as Naloxone. Within 270 days of the bill becoming law, these agencies must also begin offering voluntary, annual training to their staff on how to use these life-saving tools. While the mandate is strict for the federal government, Section 2 takes a softer approach for the private sector, directing the Secretary of Labor to issue non-mandatory guidance for businesses on how they can voluntarily stock these kits and train their teams.
For the roughly 2 million civilians working for the federal government, this bill turns the office into a safer environment by treating overdose reversal kits much like fire extinguishers or AEDs. If you are an IT specialist at a federal agency or a nurse at a VA hospital, your workplace will soon be required to have these medications on hand (Section 3). The bill specifically includes the Veterans Health Administration to ensure no loopholes exist for medical facilities. For everyone else—whether you’re coding at a startup or managing a retail store—the impact is less direct. Your employer won't be forced to buy kits, but they will receive a clear roadmap from OSHA on how to do it properly if they choose to step up. This creates a standardized playbook for HR departments who want to address the opioid crisis but aren't sure where to start with procurement or liability.
The bill sets a firm 270-day deadline for the Secretary of Labor to get the ball rolling on both the regulations for feds and the suggestions for private bosses. A key detail in Section 2 is that the training offered to employees must be voluntary and provided on an annual basis. This ensures that a worker who was trained three years ago doesn't find themselves facing an emergency with outdated knowledge. By defining "employer" through the existing Occupational Safety and Health Act of 1970, the bill relies on a familiar legal framework that most business owners already understand, though it explicitly excludes the U.S. Postal Service from these specific new guidelines.
While the bill is clear on the "what," the "how much" for the federal government will depend on the scale of medication acquisition across thousands of offices. For private business owners, the non-mandatory nature of the guidance means there are no new immediate costs or "gotcha" penalties. However, by providing a formal OSHA-backed framework, the bill lowers the barrier for entry for companies that want to include overdose kits in their first-aid protocols. The real-world goal is to move these medications out of hospitals and pharmacies and into the places where people actually are—like office buildings and job sites—so that a 911 call isn't the only hope when seconds count.